{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.8","upperLimit":"93.2","value":"50"},{"groupId":"OG001","lowerLimit":"0.6","upperLimit":"80.6","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants with a confirmed partial response (PR) or better (i.e. PR, very good partial response \\[VGPR\\], complete response \\[CR\\], and stringent complete response \\[sCR\\]) of best response, according to the International Myeloma Working Group (IMWG) Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \\<5% plasmacytomas in the bone marrow; sCR= CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR \\>= 90% reduction in serum M-component plus urine M-component \\<100 mg/24 hour (h); PR = \\>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to \\<200 mg/24 h.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose via intravenous (IV) infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG000","title":"Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg)"},{"description":"Participants with RRMM received belantamab mafodotin as dose of 3.4 mg/kg via IV infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG001","title":"Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg"}],"paramType":"NUMBER","populationDescription":"All treated population","reportingStatus":"POSTED","timeFrame":"Up to approximately 141 weeks","title":"Part 1 - Percentage of Participants With Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}